FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(State)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See Inst									
1. Name and Address ALBINI EDW	s of Reporting Person	•	2. Issuer Name and Ticker or Trading Symbol SUTRO BIOPHARMA, INC. [ STRO ]		ationship of Reporting Pers k all applicable)  Director	son(s) to Issuer			
(Last) C/O SUTRO BIC	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/05/2024	X	Officer (give title below)  CFO AND SEC	Other (specify below)			
111 OYSTER POINT BLVD.			4. If Amendment, Date of Original Filed (Month/Day/Year) 03/07/2024	6. Indiv	, , ,				
(Street) SOUTH SAN FRANCISCO	CA	94080	_		Form filed by More tha	n One Reporting Person			

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	 3. Transac Code (In 8)	tion	4. Securities Ad Disposed Of (D		4 and 5)	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Restricted Stock Units (RSUs)	(1)	03/05/2024		A		69,000		(2)	03/01/2028	Common Stock	69,000	\$0	69,000	D	

## Explanation of Responses:

 $1. \ Each \ RSU \ represents \ a \ contingent \ right \ to \ receive \ one \ (1) \ share \ of the \ Issuer's \ Common \ Stock \ upon \ settlement.$ 

(Zip)

 $2. \ The RSUs \ vest \ as \ to \ 1/4 th \ of \ the \ total \ award \ annually \ beginning \ on \ March \ 1, 2025, subject \ to \ continued \ service \ through \ each \ vesting \ date.$ 

#### Remarks:

(City)

This Form 4 amendment is being filed to correct the number of restricted stock units granted to the reporting person on March 5, 2024. The original Form 4 remains otherwise unmodified.

/s/ Edward C. Albini 03/22/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.